This is an HTML version of an attachment to the Freedom of Information request 'DG SANTE contacts with industry re. Supplementary Protection Certificates (SPCs) manufacturing waiver'.



Ref. Ares(2019)1054188 - 20/02/2019




Thank you for your message. We have passed on your messages to the person responsible for the study on 
incentives, and we will get back to you in the coming days. 
 
Best regards, 
 
Unit “Medicines: policy, authorisation and monitoring“ 
 
 
European Commission 
DG Health and Food Safety 
_____________ 
This message represents solely the views of its author and can not be regarded as the official position of the 
Commission. It is intended solely for the person to whom it is addressed and may contain confidential information. If 
you have received this message in error, please notify me as soon as possible.
 
 
 
 
From: 
  
Sent: Friday, October 13, 2017 12:41 PM 
To: SANTE PHARMACEUTICALS B5; GROW D3 
Cc: 
 
Subject: (
 sante.ddg1.b.5(2017)5458830) Fw: Copenhagen Economics study on economic impact of 
SPC, pharmaceutical incentives and rewards in Europe 
 
Dear Sir or Madam 
  
I would refer you to my email below sent to you on 2 October. Regretfully, I still have not received a reply 
from your respective services. 
  
I would appreciate it if you could forward this message to the relevant persons concerned, with the request 
that they get back to me as soon as possible. 
  
Best regards 
  
 
 
Maison européenne de la protection sociale 
  
2

 
www.esip.eu  
Twitter: @ESIP EU 
  
  
  
From: 
 
Sent: 02 October 2017 16:30 
To: xxxxxxxxxxxxxxxxxxxxxxxx@xx.xxxxxx.xx; xxxxxxx@xx.xxxxxx.xx 
Cc: 
 
Subject: Copenhagen Economics study on economic impact of SPC, pharmaceutical incentives and rewards in 
Europe  
  
Dear Sir/Madam 
  
In follow-up to the DG GROW multistakeholder workshop held on 12 September, I would like reiterate my 
concerns that as representatives of the national statutory social security organisations in the EU (the 
payers) ESIP has yet to be contacted by Copenhagen Economics  as regards the STUDY they have 
been contacted to perform ON THE ECONOMIC IMPACT OF SUPPLEMENTARY PROTECTION 
CERTIFICATES, PHARMACEUTICAL INCENTIVES AND REWARDS IN EUROPE. 
  
In this context, the TENDER SPECIFICATIONS specifically refer on page 25 to those stakeholders who 
should be consulted in the process of the study as:  
"4 The stakeholders consulted should represent all relevant and interested parties (including in particular
industry, patients, health care professionals, consumer and public health organisation, payers, academia…..) 
in a balanced way and at a European level." 
  
Could you please let me know the current state of affairs as regards the foreseen consultations with 
stakeholders, in particular the payers and let me know when we might be contacted or how we might contact 
Copenhagen Economics to ensure that we have the opportunity to give our input? 
  
Many thanks in advance for your help in this matter. 
  
Best regards 
  
  
3


 
 
 
Maison européenne de la protection sociale 
  
 
 
www.esip.eu  
Twitter: @ESIP EU 
  
  
  
  
  
  
  
  
4